Abstract BACKGROUND & AIMS Drug development for metabolic and alcohol-related liver disease (MetALD) and Alcohol-related liver disease (ALD) is emerging, but designing clinical trials remain challenging due to unknown disease progression rates and a lack of validated surrogate endpoints. We studied fibrosis progression rates and determinants of progression using dual liver biopsies and compared the […]
Fibrosis progression rate and comparison of paired liver biopsy versus non-invasive tests as surrogate endpoints for clinical trials in MetALD and ALD.
May 13, 2026
Clin Gastroenterol Hepatol